Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia – FDA Review

FDA requested that Merck conduct an additional study in primates during its review of Januvia (sitagliptin) due to concerns of necrotoxicity that were based on similar findings seen with other DPP-4 inhibitors